about
Neutrophil function in systemic lupus erythematosus and other collagen diseasesRole of beta 2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitroThe critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipinStable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity.A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coliExploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sjögren's syndromeEULAR Sjögren's syndrome disease activity index (ESSDAI): a user guideProfile of atacicept and its potential in the treatment of systemic lupus erythematosusEffects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literatureMeasures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-From BILAG to BILAG-based combined lupus assessment-30 years onIncreased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritisAntiphospholipid syndromeThe relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort studySignal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promotersFasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosusUse of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritisPhospholipid binding specificities and idiotype expression of hybridoma derived monoclonal autoantibodies from splenic cells of patients with systemic lupus erythematosus.Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception CohortAutoimmune gastrointestinal complications in patients with systemic lupus erythematosus: case series and literature review.DNA-damaging autoantibodies and cancer: the lupus butterfly theory.AIDS virus infection and autoimmunity: a perspective of the clinical, immunological, and molecular origins of the autoallergic pathologies associated with HIV disease.Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort.Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).Studies of human polyclonal and monoclonal antibodies binding to lupus autoantigens and cross-reactive antigens.Identification of candidate endothelial cell autoantigens in systemic lupus erythematosus using a molecular cloning strategy: a role for ribosomal P protein P0 as an endothelial cell autoantigen.Imaging in CNS lupus.Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort.Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort.Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium.Correlation of 9G4 idiotope with disease activity in patients with systemic lupus erythematosusThe importance of somatic mutations in the V(lambda) gene 2a2 in human monoclonal anti-DNA antibodies.EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.Animal models of the antiphospholipid syndrome.Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus.The prevalence of antibodies to anionic phospholipids in patients with the primary antiphospholipid syndrome, systemic lupus erythematosus and their relatives and spouses.Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome.Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems.
P50
Q24514489-33170612-F7E8-4644-A0C4-10F458E806F0Q24563574-A443A4E8-9A7D-427C-9491-0349A07F2EB1Q24798707-62FF0A3D-40C6-49E3-914B-4D5944C248C8Q24812196-C7246C44-6ECC-42C5-AC84-B0933364D4B1Q25255895-2F0A811B-EA86-43E9-B8BF-7ED71CE48850Q26770648-32D1883F-78BE-49CC-971F-B2A57B3D64F7Q26778262-C05B615C-148C-47D8-9AB8-44727E47A4DAQ26849719-1C631C56-6770-4392-8DB7-9194938319C1Q27015934-363DAE01-CECC-4E34-A837-A6936103E0B1Q27021322-D1ACCEAF-3494-42FB-B33A-726F7941EB93Q28081809-BCB7BE11-0A8F-456C-8D94-722578B65A89Q28191467-07351B76-5F10-43AD-B2A5-9B8E6E44A194Q28195585-2081A2CE-6E14-4FFC-9802-AEF2D47289D2Q28212163-0D46ED75-8A55-4B37-9181-AB4E62513FA6Q28293210-FB0DE5EB-0A03-4992-9C37-E3C6A6F57A25Q28319260-1546E4A1-405F-4C43-93F1-9A34B87BDB55Q28345031-F2976F61-B4A5-413B-8A29-9B9315C42009Q28367919-ABB01A76-F3A8-460F-B427-5523325B240BQ28608340-EB412F88-4E55-4195-BDCA-C9092C13B07BQ30243900-86A3207F-E01B-4E73-B21F-144B8E4EF09CQ30251723-D3484A8B-F9CB-477A-9A96-35BFCBB843E2Q30381934-8CBF9370-FBAF-42F6-89D1-D3A09C883568Q30560952-DED53300-7793-45D0-BBBA-B721DE5ED69EQ30791606-70E72B20-9B31-46A9-9271-465CFB707063Q30823425-89180446-4A73-4091-A421-A321C640AB48Q30832522-4DBC90E3-CCBB-4949-B38A-2B82CD9B4C94Q30894091-B3A0A3AF-6FE0-40EE-B0D5-A4C06CC35103Q30943894-6E120F9D-B563-4094-82C4-0F4C356BFAC2Q31003776-A348B7DF-90AA-48AA-B5EC-E87B7EE7FC3DQ31122937-17849797-8237-421C-AD85-0088F8C70AACQ31145074-9A9A4E48-30BC-4C92-B8AD-728B884036FFQ31145428-3D190F56-ECB8-477D-A0C6-221E6D52B88CQ31956873-ACA251F1-A7D5-4900-9A92-841675CBBE6CQ32180060-DCD84A8C-1E95-4582-942A-64CA6024422AQ33284736-61AE6A97-D911-40AA-8DC2-8BB25F509511Q33329846-18FF0F9E-66B5-4416-A727-13EBDB0CAD55Q33331672-945C2E07-A44A-462F-81DE-87B20E8A7703Q33332505-22D0513F-EDC9-434C-B299-103B89C22498Q33337503-CA5654F0-6E83-466E-9903-FD024487415FQ33346622-BA0C005E-2804-4E4D-BEDC-00AD578B7835
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
David A. Isenberg
@ast
David A. Isenberg
@en
David A. Isenberg
@es
David A. Isenberg
@nl
David A. Isenberg
@sl
type
label
David A. Isenberg
@ast
David A. Isenberg
@en
David A. Isenberg
@es
David A. Isenberg
@nl
David A. Isenberg
@sl
altLabel
David Isenberg
@en
prefLabel
David A. Isenberg
@ast
David A. Isenberg
@en
David A. Isenberg
@es
David A. Isenberg
@nl
David A. Isenberg
@sl
P1006
P214
P244
P1006
P106
P1153
36051280800
P21
P213
0000 0003 7456 4020
P214
P244
P31
P496
0000-0001-9514-2455
P569
1949-10-20T00:00:00Z
P734
P735
P7859
lccn-n88044995